LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf Intellipharmaceutics International Inc. (“Intellipharmaceutics” or the “Company”) (NASDAQ: IPCI) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Intellipharmaceutics investigation page on our website at glancylaw.com/case/intellipharmaceutics-international-inc.
On July 26, 2017, Intellipharmaceutics disclosed that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (“FDA”) voted 22 to 1 against approval of the Company’s New Drug Application for Rexista, an opioid painkiller. The FDA committees also voted that Rexista had not demonstrated properties that can be expected to deter abuse by the intravenous route, and that there was insufficient data to support inclusion of language regarding abuse-deterrent properties in the product label for the intravenous route of administration.
On this news, the Company’s share price fell $1.13 per share, or 45.3% on July 27, 2017, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Intellipharmaceutics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.